Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus.

The article presents a clinical research study that examined the safety and metabolic effects of high-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) in patients with newly diagnosed type 1 diabetes mellitus, which is the result of a cell-mediated autoimmune attack against pancreatic beta cells. The authors concluded that high-dose immunosuppression and AHST were performed with acceptable toxicity. Beta cell function was increased in almost all patients with AHST, which also induced prolonged insulin independence in the majority of patients.